CTOs on the Move

Versicolor Technologies

www.versicolortechnologies.com

 
Versicolor Technologies has developed the world`s first cosmetic and therapeutic technology platform to address pigmentation and skin aging, by leveraging small molecule compounds produced naturally in the human microbiome.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

MedPoint Communications

MedPoint Communications, Inc is a Evanston, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Sleep Disorder Center of Louisiana

Sleep Disorder Center of Louisiana is a Lake Charles, LA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Complete Healthcare Communications Inc

Complete Healthcare Communications Inc is a Chadds Ford, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

www.mavericktx.com

Maverick Therapeutics is pioneering the next generation of redirected T-cell targeted immunotherapies. Mavericks highly innovative platform, COBRA™, is the most advanced bispecific T-cell engaging platform in its class, designed to safely target solid tumors with highly specific and potent activity.

PanOptica

At PanOptica, our aim is to develop new ocular therapies that help patients see their very best throughout their lives. Many patients with common eye diseases suffer debilitating vision loss, despite currently available treatments. At PanOptica, we understand the critical role vision plays in a patient`s quality of life. And we know the frustration eye care professionals face when they are unable to treat their patients successfully. Today, significant progress is being made in the field of ophthalmology, with small laboratories and large pharmaceutical companies alike exploring newer, more effective treatments for sight-threatening diseases. PanOptica seeks to license and develop these innovative therapeutics, which may include improvements to existing therapies or entirely new treatments for previously untreatable disorders. Our lead development compound, PAN-90806 , is a novel, small-molecule selective VEGF receptor antagonist that shows promise as a topical treatment for wet age-related macular degeneration and diabetic retinopathy.